HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression of macrophage migration-inhibitory factor is correlated with progression in oral cavity carcinomas.

AbstractBACKGROUND:
We have previously reported that macrophage migration-inhibitory factor (MIF) is associated with an unfavorable prognosis in hypopharyngeal carcinoma. Here, we quantified MIF expression in oral cavity carcinomas and looked for possible correlations with clinical outcome.
MATERIALS AND METHODS:
MIF expression was assessed by immunohistochemistry in a cohort of 154 oral cavity carcinomas and was compared to eight specimens of tumor-free epithelia, 32 cases of low-grade dysplasia and 137 cases of high-grade dysplasia.
RESULTS:
Marked increases in MIF-immunostaining intensity and MIF-positive tissue areas were seen in carcinomas as compared to dysplasia (p<10(-6)). MIF expression showed no correlation with recurrence, but was significantly higher (p=0.01) when a second primary tumor occurred. In addition, HPV(+) malignancies exhibited lower MIF expression.
CONCLUSION:
Our study revealed an association between tissue MIF levels and tumor progression in oral cavity carcinomas. Of note, high-level MIF expression was found in patients developing a second tumor during the follow-up period.
AuthorsNadège Kindt, Jérôme Lechien, Christine Decaestecker, Alexandra Rodriguez, Gilbert Chantrain, Myriam Remmelink, Guy Laurent, Hans-Joachim Gabius, Sven Saussez
JournalAnticancer research (Anticancer Res) Vol. 32 Issue 10 Pg. 4499-505 (Oct 2012) ISSN: 1791-7530 [Electronic] Greece
PMID23060578 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Macrophage Migration-Inhibitory Factors
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma (pathology)
  • Disease Progression
  • Female
  • Humans
  • Immunohistochemistry
  • Macrophage Migration-Inhibitory Factors (analysis, biosynthesis)
  • Male
  • Middle Aged
  • Mouth Neoplasms (pathology)
  • Neoplasms, Second Primary (pathology)
  • Prognosis
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: